Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) : $3.58 million worth of transactions were on upticks in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), compared to $3.07 million on downticks. The ratio between the two was 1.17, whereas, the net money flow stood at a healthy $0.51 million on Wednesdays session. The consistent buying on upticks in the stock accounted for $0.98million worth of trades. The total money flow into the stock stood at $0.98 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.43%. The stock was trading at $83.08, with a drop of $0.36 over the previous days close. The stock recorded 1.44% for the week.
In an insider trading activity, The Securities and Exchange Commission has divulged that Boger Joshua S, director of Vertex Pharmaceuticals Inc / Ma, had unloaded 5,130 shares at an average price of $87.19 in a transaction dated on June 22, 2016. The total value of the transaction was worth $447,285. Currently the company Insiders own 1.8% of Vertex Pharmaceuticals Incorporated shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.03% . Institutional Investors own 97.02% of Vertex Pharmaceuticals Incorporated shares. During last six month period, the net percent change held by insiders has seen a change of -3.03%.
The company shares have dropped -33.88% from its 1 Year high price. On Aug 10, 2015, the shares registered one year high at $143.45 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $87.86 and the 200 Day Moving Average price is recorded at $91.61. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $83.85 and $82.69 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $85.94. The buying momentum continued till the end and the stock did not give up its gains. It closed at $85.00, notching a gain of 1.87% for the day. The total traded volume was 1,754,296 . The stock had closed at $83.44 on the previous day.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.